BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 33337372)

  • 1. Association of TDP-43 Pathology with Global and Regional 18F-Florbetapir PET Signal in the Alzheimer's Disease Spectrum.
    Teipel SJ; Temp AGM; Levin F; Dyrba M; Grothe MJ;
    J Alzheimers Dis; 2021; 79(2):663-670. PubMed ID: 33337372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
    Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
    J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study.
    Josephs KA; Dickson DW; Tosakulwong N; Weigand SD; Murray ME; Petrucelli L; Liesinger AM; Senjem ML; Spychalla AJ; Knopman DS; Parisi JE; Petersen RC; Jack CR; Whitwell JL
    Lancet Neurol; 2017 Nov; 16(11):917-924. PubMed ID: 28919059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antemortem-Postmortem Correlation of Florbetapir (18F) PET Amyloid Imaging with Quantitative Biochemical Measures of Aβ42 but not Aβ40.
    Beach TG; Maarouf CL; Intorcia A; Sue LI; Serrano GE; Lu M; Joshi A; Pontecorvo MJ; Roher AE
    J Alzheimers Dis; 2018; 61(4):1509-1516. PubMed ID: 29376867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antemortem basal forebrain atrophy in pure limbic TAR DNA-binding protein 43 pathology compared with pure Alzheimer pathology.
    Teipel SJ; Grothe MJ;
    Eur J Neurol; 2022 May; 29(5):1394-1401. PubMed ID: 35122358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of florbetapir-PET for imaging beta-amyloid pathology.
    Clark CM; Schneider JA; Bedell BJ; Beach TG; Bilker WB; Mintun MA; Pontecorvo MJ; Hefti F; Carpenter AP; Flitter ML; Krautkramer MJ; Kung HF; Coleman RE; Doraiswamy PM; Fleisher AS; Sabbagh MN; Sadowsky CH; Reiman EP; Zehntner SP; Skovronsky DM;
    JAMA; 2011 Jan; 305(3):275-83. PubMed ID: 21245183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia.
    Akhtar RS; Xie SX; Chen YJ; Rick J; Gross RG; Nasrallah IM; Van Deerlin VM; Trojanowski JQ; Chen-Plotkin AS; Hurtig HI; Siderowf AD; Dubroff JG; Weintraub D
    PLoS One; 2017; 12(5):e0177924. PubMed ID: 28542444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.
    Tosun D; Landau S; Aisen PS; Petersen RC; Mintun M; Jagust W; Weiner MW;
    Brain; 2017 May; 140(5):1499-1512. PubMed ID: 28334939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of Cortical and Subcortical Amyloid Burden across Stages of Preclinical Alzheimer's Disease.
    Edmonds EC; Bangen KJ; Delano-Wood L; Nation DA; Furst AJ; Salmon DP; Bondi MW;
    J Int Neuropsychol Soc; 2016 Nov; 22(10):978-990. PubMed ID: 27903335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
    Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
    Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease.
    Toledo JB; Bjerke M; Da X; Landau SM; Foster NL; Jagust W; Jack C; Weiner M; Davatzikos C; Shaw LM; Trojanowski JQ;
    JAMA Neurol; 2015 May; 72(5):571-81. PubMed ID: 25822737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Florbetapir Regional Distribution in Cerebral Amyloid Angiopathy and Alzheimer's Disease: A PET Study.
    Planton M; Saint-Aubert L; Raposo N; Payoux P; Salabert AS; Albucher JF; Olivot JM; Péran P; Pariente J
    J Alzheimers Dis; 2020; 73(4):1607-1614. PubMed ID: 31958082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimer's Disease Neuropathological Changes.
    Buciuc M; Wennberg AM; Weigand SD; Murray ME; Senjem ML; Spychalla AJ; Boeve BF; Knopman DS; Jack CR; Kantarci K; Parisi JE; Dickson DW; Petersen RC; Whitwell JL; Josephs KA
    J Alzheimers Dis; 2020; 73(4):1511-1523. PubMed ID: 31929165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationships between objectives sleep parameters and brain amyloid load in subjects at risk for Alzheimer's disease: the INSIGHT-preAD Study.
    Ettore E; Bakardjian H; Solé M; Levy Nogueira M; Habert MO; Gabelle A; Dubois B; Robert P; David R
    Sleep; 2019 Sep; 42(9):. PubMed ID: 31267124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of PET-based stages of amyloid deposition with neuropathological markers of Aβ pathology.
    Teipel SJ; Temp AGM; Levin F; Dyrba M; Grothe MJ;
    Ann Clin Transl Neurol; 2021 Jan; 8(1):29-42. PubMed ID: 33137247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Semiautomated Method for Quantification of F 18 Florbetapir PET Images.
    Joshi AD; Pontecorvo MJ; Lu M; Skovronsky DM; Mintun MA; Devous MD
    J Nucl Med; 2015 Nov; 56(11):1736-41. PubMed ID: 26338898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.
    Okamura N; Yanai K
    IDrugs; 2010 Dec; 13(12):890-9. PubMed ID: 21154149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.